HURA — TuHURA Biosciences Cashflow Statement
0.000.00%
- $171.23m
- $158.85m
Annual cashflow statement for TuHURA Biosciences, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -9.13 | -38.3 | -22.7 | -14.6 | -8.32 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.702 | 22.1 | 2.26 | 4.92 | 0.798 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.487 | -2.65 | -0.055 | -2.19 | 0.291 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -7.93 | -18.9 | -20.4 | -11.9 | -7.18 |
Capital Expenditures | — | -0.008 | 0 | -0.232 | -0.02 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | 0.972 | 0 | — | — |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Cash from Investing Activities | — | 0.964 | 0 | -0.232 | -0.02 |
Financing Cash Flow Items | -0.025 | -0.03 | 0 | — | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 6.6 | 26 | 21.6 | 1.85 | 10.6 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.33 | 8.14 | 1.24 | -10.2 | 3.37 |